Thyroid eye disease is an autoimmune condition with an active and inactive phase resulting in proptosis, eyelid retraction, and periorbital edema of varying severity. Symptoms range from mild eye irritation to vision loss from compressive optic neuropathy requiring medical and possibly acute surgical intervention. Active disease typically lasts one to three years before burn-out occurs; reactivation and irreversible vision loss is uncommon. An ophthalmologist can be of unique benefit to the patient in three valuable ways: (1) early diagnosis and referral for systemic treatment, (2) protection against the vision threatening effects of the disease, and (3) restoration of the patient’s natural appearance.
KeywordsGraves’ ophthalmopathy Graves’ orbitopathy Thyroid-associated orbitopathy Graves’ disease Immunotherapy Orbital radiotherapy Rituximab Teprotumumab Decompression Thyroid eye disease
- 1.Bartley GB, Fatourechi V, Kadrmas EF, JACOBSEN SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmo. 1996;121(3):284–90.Google Scholar
- 2.Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol. 1997;47(1):9–14.Google Scholar
- 3.Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015.Google Scholar
- 5.Clinical Features—VISA Classification—Thyroid Eye Disease [Internet]. International Thyroid Eye Disease Society. http://thyroideyedisease.org/clinical-features-visa-classification (2019). Accessed 10 Apr 2019.
- 8.Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. New Engl. J Med. 1989;321(20):1349–52.Google Scholar
- 11.Nerad JA. Techniques in ophthalmic plastic surgery: a personal tutorial. Elsevier Health Sciences; 11 Nov 2009.Google Scholar
- 12.Tomsak MR, EL Toukhy R.E. Thyroid ophthalmopathy: levine. In: Nerad J, Grossinklaus H, editors. Ophthalmology clinics of North American, vol. 9. No. 4. WB Saunders; December 1996.Google Scholar